Abu Dhabi, UAE | Stem Cell Center

Since 2000, Aesthetic Polyclinic has had the privilege to serve the residents of Abu Dhabi and Al Ain with superior Aesthetic services from Plastic surgery to Dermatology, IPL Hair removal, Cosmetic and general dentistry, slimming and body treatments and specialized skin care.

As one of Abu Dhabis top healthcare clinics, we are committed to our vision of meeting the growing needs of our clients and patients through through the continuous use of latest medical technology and services, delivered by professional, efficient and customer centric staff. We understand the true meaning of Customer service excellence and strive to achieve it through Quality, Innovation, Excellence, Customer Focus and Leading Technology.

Our organization has been focused on growing and enhancing our services. Aesthetic Polyclinic, formally known as Aesthetic Skin Care centre, started as one of the first medical spas in Abu Dhabi in 2000. In 2009 Aesthetic became a polyclinic offering Dermatology and Plastic Surgery. In 2013, we expanded our medical services into a brand new state of the art dedicated medical building which included the addition of dental and orthodontic services.

Our clinic nestles away from the pressure of everyday life, so our clients may benefit from their time with Aesthetic physically and emotionally. We at Aesthetic recognize and affirm the uniqueness of each man and woman and our image consultants strive to achieve their clients goals through advanced technology and highly skilled medical staff, who believe in creating natural looking results that are described as You just better!. Aesthetic respects each clients will of looking as good on the outside as they feel on the inside by offering individually tailored packages of care enabling them to make informed decisions to achieve their Perfect Image.

It is with great pride that I share our history and efforts within our community and thank all of our clients and patients for their continued confidence and loyalty to our organization.

See the rest here:
Abu Dhabi, UAE | Stem Cell Center

UCLA researchers identify compound that could improve lung disease treatment – Daily Bruin

A UCLA study identified a chemical compound that may improve lung health, potentially suggesting new approaches to preventing and treating lung diseases.

According to the study published Tuesday in Cell Reports, the UCLA team discovered a compound now named Wnt Inhibitor Compound 1, or WIC1, that successfully improved the health of isolated cancerous human and mouse airway cells.

The compound targets a group of molecules, called the Wnt/-catenin signaling pathway, that is more activated in the lungs of people with precancerous lesions or lung cancer than in the lungs of healthy people. Elevated activity in this pathway has also been linked to lung cancer in other studies.

The researchers tested around 20,000 compounds on their abilities to block this pathway in the process of identifying WIC1.

The researchers also found that the compound WIC1 was far less toxic than other known inhibitors of the Wnt/-catenin signaling pathway. The compound could therefore be used to develop safer drugs to prevent and treat lung diseases linked to the pathway.

Led by Brigitte Gomperts, a UCLA professor of pediatrics and of pulmonary medicine, and Cody Aros, a molecular biology graduate student, the team is planning to further investigate the safety of WIC1 and the mechanism by which it blocks the pathway.

The study was supported in part by the National Institutes of Health, the National Cancer Institute and the Broad Stem Cell Research Center Training Program.

The rest is here:
UCLA researchers identify compound that could improve lung disease treatment - Daily Bruin

Caution: Higher Radiation Dose Linked to Worse NHL Outcomes – Medscape

ORLANDO, Florida Increasing the dose of total body irradiation (TBI) given to patients with non-Hodgkin lymphoma (NHL) who are undergoing reduced-intensity conditioning prior to stem cell transplant may lead to worse survival, investigators caution.

The finding comes from a study in 413 adults with NHL who underwent a first allogeneic hematopoietic stem cell transplant (alloHCT) with a fludarabine-based reduced-intensity conditioning regimen that included TBI.

Dr Mehdi Hamadani

In this patient population, relapse is the most common cause of therapy failure. One approach to decreasing relapse risk has been to increase the intensity of the radiation component from 2 Gy to 4 Gy, but the effect of the higher radiation doses on nonrelapse mortality is uncertain, explained lead investigator Mehdi Hamadani, MD, from the Medical College of Wisconsin in Milwaukee.

The results showed a significantly higher incidence of nonrelapse mortality and significantly worse overall survival for patients who received the higher radiation dose.

"Relative to the more standard fludarabine/2-Gy TBI conditioning, the 4-Gy TBI-based approach does not seem to increase the risk of graft-vs-host disease, either acute or chronic, [but] it provides no benefit in terms of graft failure. This higher 4-Gy TBI approach is associated with a significantly increased risk of nonrelapse mortality that clearly translates into inferior survival with this approach," Hamadi reported.

The study was presented here at Transplantation and Cellular Therapy (TCT) 2020, a joint meeting of the American Society for Blood and Marrow Transplantation and the Center for International Blood and Marrow Transplant Research (CIBMTR).

Mazyar Shadman, MD, MPH, from the Fred Hutchinson Cancer Research Center in Seattle, Washington, who was comoderator of the session at which the study was presented, told Medscape Medical News, "It's mainly an institutional decision: you see a patient and you think they have high-risk disease, so you go up a little bit on the dose, but the data were actually very informative. You're not getting any better disease control, and you have more toxicity, so I think this is a very important study; I think a nonrandomized trial has its limitations, but it's still very helpful," he said.

The investigators studied data on 413 adults with NHL in the CIBMTR registry who received a first alloHCT from either a matched-related or unrelated donor from 2008 through 2017 and who underwent a reduced-intensity conditioning regimen with fludarabine plus either 2 Gy (349 patients) or 4 Gy (64 patients) of TBI.

The baseline characteristics of the two cohorts were generally similar except that in the 4-Gy group, a higher proportion of patients had Karnofsky Performance scores >90% (P = .01), and a lower proportion of patients had a Hematopoietic Cell Transplantation-specific Comorbidity Index of 3 (P = .003).

The investigators found that compared with the 2-Gy TBI dose, the 4-Gy dose was associated with a hazard ratio (HR) for nonrelapse mortality of 1.79 (P = .02) and an HR for inferior overall survival of 1.51 (P = .03).

In contrast, there were no significant differences between the dosing groups for either NHL relapse/progression (HR, 0.78; P = .33) or progression-free survival (HR, 1.09; P = .61).

The 5-year adjusted nonrelapse mortality rate for the 2-Gy group was 28%, compared with 47% for the 4-Gy group (P = .005). Other adjusted 5-year outcomes were as follows: risk for relapse/progression, 35% vs 29%; progression-free survival, 37% vs 24% (P = .03); and overall survival, 51% vs 31% (P = .001).

The rate of graft failure at 100 days was 0.6% in the 2-GY group, compared with 1.6% in the 4-Gy group, but this difference was not significant.

The most common cause of death in each group was relapse.

Session comoderator Yago Nieto, MD, PhD, from the University of Texas MD Anderson Cancer Center in Houston, commented in an interview with Medscape Medical News that a conditioning regimen with fludarabine and 4-Gy TBI is not commonly used in the United States.

He also noted that Hamadani and colleagues evaluated patients with lymphoma of several histologies. He pointed out that radiosensitivity specifically to TBI differs between aggressive and indolent lymphomas.

"Indolent lymphoma is more sensitive to TBI than diffuse large B-cell lymphoma, for example. The numbers for each subgroup in this study were small, and I don't think it's empowered to address this question, but one could speculate that patients with follicular lymphoma might benefit more from a higher TBI dose than those with aggressive histologies," he said.

No source of funding for the study has been disclosed. Hamadani, Nieto, and Shadman have disclosed no relevant financial relationships.

Transplantation and Cellular Therapy (TCT) 2020: Abstract 24. Presented February 19, 2020.

For more from Medscape Oncology, follow us on Twitter: @MedscapeOnc.

Continued here:
Caution: Higher Radiation Dose Linked to Worse NHL Outcomes - Medscape

Cord Stem Cell Banking Market 2020 to Witness Great Growth || Key Players Cryo-Save AG, Lifecell, StemCyte India Therapeutics Pvt. Ltd, Viacord,…

By keeping an eye on the market conditions and market trends, market research study is initiated depending on clients requirements to form this business document. This Cord Stem Cell Banking market report gives the details about market definition, market drivers, market restraints, market segmentation with respect to product usage and geographical conditions, key developments taking place in the market, competitor analysis, and the research methodology. One of the most noteworthy parts of this Cord Stem Cell Banking Market report is competitor analysis with which businesses can estimate or analyse the strengths and weaknesses of the competitors to gain benefits.

Global Cord stem cell banking market is estimated to reach USD 13.8 billion by 2026 registering a healthy CAGR of 22.4%. The increasing number of parents storing their childs cord blood, acceptance of stem cell therapeutics, high applicability of stem cells are key driver to the market.

Request for sample copy or PDF Here https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-cord-stem-cell-banking-market&raksh

Few of the major market competitors currently working in the globalcord stem cell banking marketareCBR Systems, Inc., Cordlife, Cells4Life Group LLP, Cryo-Cell International, Inc., Cryo-Save AG, Lifecell, StemCyte India Therapeutics Pvt. Ltd, Viacord, SMART CELLS PLUS., Cryoviva India, Global Cord Blood Corporation, National Cord Blood Program, Vita 34, ReeLabs Pvt. Ltd., Regrow Biosciences Pvt. Ltd. , ACROBiosystems., Americord Registry LLC., New York Blood Center, Maze Cord Blood, GoodCell., AABB, Stem Cell Cryobank, New England Cryogenic Center, Inc. among others

Market Definition: Global Cord Stem Cell Banking Market

Cord stem cells banking is nothing but the storing of the cord blood cell contained in the umbilical cord and placenta of a newborn child. This cord blood contains the stem cells which can be used in future to treat disease such as leukemia, thalassemia, autoimmune diseases, and inherited metabolic disorders, and few others.

Segmentation: Global Cord Stem Cell Banking Market

Cord Stem Cell banking Market : By Storage Type

Cord Stem Cell banking Market : By Product Type

Cord Stem Cell banking Market : By Service Type

Cord Stem Cell banking Market : By Indication

Cord Stem Cell banking Market : By Source

Cord Stem Cell banking Market : By Geography

Browse Detailed TOC, Tables, Figures, Charts and Companies @https://www.databridgemarketresearch.com/toc?dbmr=global-cord-stem-cell-banking-market&raksh

Key Developments in the Cord Stem Cell banking Market:

Cord Stem Cell banking Market : Drivers

Cord Stem Cell banking Market : Restraint

Competitive Analysis: Global Cord Stem Cell Banking Market

Global cord stem cell banking market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions and others to increase their footprints in this market. The report includes market shares of cord stem cell banking market for Global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Scope of the Cord Stem Cell banking Market Report :

The report shields the development activities in the Cord Stem Cell banking Market which includes the status of marketing channels available, and an analysis of the regional export and import. It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments. This will benefit the reports users, that evaluates their position in Cord Stem Cell banking market as well as create effective strategies in the near future.

Want Full Report? Enquire Here @https://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-cord-stem-cell-banking-market&raksh

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475Mail:[emailprotected]

Read this article:
Cord Stem Cell Banking Market 2020 to Witness Great Growth || Key Players Cryo-Save AG, Lifecell, StemCyte India Therapeutics Pvt. Ltd, Viacord,...

Global Cell and Gene Therapy Consumables Market Revenue Expected to Reach USD 6999 Million By 2027 – Northwest Trail

Facts and Factors Market Researchhas published a new report titled Cell and Gene Therapy Consumables Market By Product Type (Kits & Buffers, Diagnostic Assay, Culture Medium, and Cryopreservation Media) and By Application/ Therapeutics (Cardiovascular, Urology, Dermatology, Critical Care, Respiratory, Endocrine & Metabolic, Neuroscience, Hematology & Oncology, Obstetrics, Immunology, and Gastroenterology): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018 2027.

According to the report, the globalcell and gene therapy consumables marketis predicted to be valued at approximately USD 641 million in 2018 and is expected to reach a value of around USD 6,999 million by 2027, at a CAGR of around 30.43 % between 2019 and 2027.

Cells are the key building blocks of all living things, while genes are located deep inside the cells. Genes are tiny parts of DNA that carry heritable information and directions for producing proteins that help in building and maintaining the body. Cell and gene therapies are the overlapping domains of biomedical research activities as well as biomedical treatment. The key objective of both these therapies is to treat, prevent, and cure ailments. Moreover, both these approaches have the prospective to lessen the core causes of genetic disorders as well as acquired diseases. However, the functioning of cell and gene treatment varies.

Request Free Sample Copy of Research Report@www.fnfresearch.com/sample/cell-and-gene-therapy-consumables-market-by-product-107

(The sample of this report is readily available on request).

This Free report sample includes:

Furthermore, the main aim of cell treatment is to treat disorders through restoration or alteration of certain sets of cells or through the use of the cells to carry therapy throughout the body. In cell treatment, cells are cultured or altered out of the body before injecting them into the body of the patient. The cells can be acquired from the patient in the form of autologous cells or from a donor in the form of allogeneic cells.

Apparently, the key objective of gene therapy is to treat diseases through the replacement, inactivation, or introduction of genes into cells i.e. either inside the body or outside of the body. Moreover, few of the treatments are considered as both cell and gene treatments. They work by shifting genes in particular types of cells and then injecting them back into the body.

Rising occurrence of target ailments to drive the market trends

The growth of the market during the forecast period is due to the high rate of incidences of chronic ailments including cancer and heart disorders. Apart from this, a rise in the occurrence of these disorders produces lucrative demand for enhanced therapies and this will culminate in the market demand over the forecast period.

Furthermore, a rise in the awareness about the gene & cell therapies will steer the market growth during the period from 2019 to 2027. Nonetheless, conducting randomized control tests will inhibit the expansion of the market during the forecast timeline. However, the growing trend for treating neurodegenerative ailments through the use of gene treatment will proliferate the market growth over the forecast period.

Kits & Buffers segment to dominate the product type landscape in terms of revenue

The growth of the segment during the forecast timespan is due to high demand for the kits & buffers across hospitals & clinics during the cell & gene treatments.

Inquire more about this report before purchase@www.fnfresearch.com/inquiry/cell-and-gene-therapy-consumables-market-by-product-107

Cardiovascular application to accrue massive gains in terms of revenue by 2027

The growth of the segment is due to the high occurrence of heart diseases caused due to the result of inherited disorders like high blood pressure and diabetes.

North America to dominate the regional market growth in terms of value

The growth of the market in the region is due to the major presence of giant players along with the high awareness about these cell & gene treatments. The U.S. is likely to be the major revenue contributor of the region during the forecast timeline.

Some of the key players in the market include Amgen Inc., ATLANTA BIOLOGICALS, bluebird bio, Inc., Cook, Dendreon Pharmaceuticals, LLC, Fibrocell Science, Inc., General Electric, Kolon TissueGene, Inc., Orchard Therapeutics plc., Pfizer, Inc., PromoCell GmbH, RENOVA THERAPEUTICS, Sibiono GeneTech Co. Ltd., Spark Therapeutics, Inc., Vericel, Helixmith Co., Ltd., and Vitrolife.

This report segments the Cell and Gene Therapy Consumables market as follows:

Cell and Gene Therapy ConsumablesMarket:By Product TypeSegment Analysis

Cell and Gene Therapy ConsumablesMarket: ByApplication/ TherapeuticsSegment Analysis

Request Customized Copy of Report @www.fnfresearch.com/customization/cell-and-gene-therapy-consumables-market-by-product-107

Cell and Gene Therapy Consumables Market: Regional Segment Analysis

About Us:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our clients/customers conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Contact Us:

Facts & Factors

Global Headquarters

Level 8, International Finance Center, Tower 2,8 Century Avenue, Shanghai,Postal 200120, ChinaTel: +86 21 80360450

Email:sales@fnfresearch.com

Web:www.fnfresearch.com

See the original post here:
Global Cell and Gene Therapy Consumables Market Revenue Expected to Reach USD 6999 Million By 2027 - Northwest Trail

Stem Cell Therapy Market: Business Opportunities, Current Trends and Industry Analysis by 2018 2028 – Instant Tech News

Stem Cell Therapy Market Insights 2019, is a professional and in-depth study on the current state of the global Stem Cell Therapy industry with a focus on the Global market. The report provides key statistics on the market status of the Stem Cell Therapy manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2019-2025 global Stem Cell Therapy market covering all important parameters.

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787&source=atm

The key points of the Stem Cell Therapy Market report:

The report provides a basic overview of the Stem Cell Therapy industry including its definition, applications and manufacturing technology.

The report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2019-2025 market shares for each company.

Through the statistical analysis, the report depicts the global total market of Stem Cell Therapy industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

The report then estimates 2019-2025 market development trends of Stem Cell Therapy industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out.

The report makes some important proposals for a new project of Stem Cell Therapy Industry before evaluating its feasibility.

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1787&source=atm

There are 3 key segments covered in this report: competitor segment, product type segment, end use/application segment.

For competitor segment, the report includes global key players of Stem Cell Therapy are included:

Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=1787&source=atm

Reasons to Purchase this Report:

* Estimates 2019-2025 Stem Cell Therapy market development trends with the recent trends and SWOT analysis

* Market dynamics scenario, along with growth opportunities of the market in the years to come

* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects

* Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.

* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years

* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Read more from the original source:
Stem Cell Therapy Market: Business Opportunities, Current Trends and Industry Analysis by 2018 2028 - Instant Tech News

Anatomy of a grant: Ashley Kramer’s yearlong journey to finding her doctoral thesis – The South End

He asked her for a list of dream projects she would love to investigate. What followed was a year of challenges, stresses and the ultimate reward guided intellectual freedom toward scientific discovery.

Ashley Kramer, a student at the Wayne State University School of Medicine, is enrolled in the schools M.D.-Ph.D. program, an eight-year commitment broken down into three parts the first two years of medical school, four years of graduate school, then the final two years of medical school. Like all M.D./Ph.D. students at the medical school, Kramer had to complete research rotations with faculty she thought would make good dissertation advisors.

Because I have always loved stem cell biology and had experience working with zebrafish in the past, I decided to do an eight-week rotation in Dr. Thummels lab between my medical year one and medical year two, and made the decision that this was absolutely the perfect lab for me, she said.

Ryan Thummel, Ph.D., is an associate professor of Ophthalmology, Visual and Anatomical Sciences. His lab focuses on retinal development and regeneration in zebrafish, an attractive model to study neurodegenerative diseases because of its ability to regenerate neuronal tissues. Zebrafish fully regenerate their retinas in just a matter of weeks, an ability mammals lack.

Zebrafish and mammals both have a cell called Mller glia that supports retinal neurons. In zebrafish, however, these cells convert to stem cells and are responsible for retinal regeneration.

At the end of the rotation, Dr. Thummel floated the crazy idea of starting to work on this grant, a 70-plus page monster undertaking, during my M2 year, and I immediately jumped at the opportunity. I was excited at the idea of having a four-year research project completely planned out by the time I started my Ph.D. after M2 so I could hit the ground running after the dreaded STEP 1, Kramer said.

I came to him two days later with a nine-page document of project ideas. We sat down for three hours discussing projects and came up with a top-two list of cohesive projects for me to move forward with as a grant and thesis, she said. From there, it was a nearly yearlong process of writing, meeting, revising and repeating for each of the many sections of the grant.

The effort was worth it. Kramer secured a five-year, $294,102 grant from the National Eye Institute of the National Institutes of Health last year to study the molecular mechanisms of retinal regeneration in zebrafish, an organism that exhibits a remarkable capacity for regeneration.

"Ashley is a dedicated young scientist and worked very hard on this grant application," Dr. Thummel said.

The grant is one of the NIHs Ruth L. Kirschstein National Research Service awards, also known as an F30. The project, Elucidating the role of DNA methyltransferases in epigenetic regulation of retinal regeneration in the zebrafish, started last month. She is the principal investigator.

This was an incredibly challenging experience that allowed me to grow immensely as a scientist. Grant writing, planning effective and novel longitudinal scientific investigations, and time management will all be critical skills for me moving forward in my career as a physician scientist, she said. I cannot thank Dr. Thummel and my past advisors enough for all of their mentoring and support in the last ten years who have gotten me to where I am today, and I am looking forward to the rest of my training here at Wayne State and beyond.

Kramer earned her bachelors degree in Genetics, Cell Biology and Development from the University of Minnesota in 2014. Her love of research and stem cell biology started when she was an undergraduate research assistant there.

Nearly a decade later, she is studying how epigenetic marks are added to, and removed from, genes in zebrafish retinal stem cells during the process of retinal regeneration. The role of epigenetics in the body is akin to traffic signs on the road.

If roads had no traffic lights, stop signs or barricades, it would be complete chaos. The same is true for your cells. If you used every single gene encoded in your DNA 100% of the time, your cells would be chaos. Epigenetics is what is responsible for telling your skin cell to be a skin cell and your liver cell to be a liver cell, while they both have the exact same underlying DNA sequence, Kramer said. There are various different epigenetic marks that decorate the DNA without actually changing the sequence. These marks come in many forms and can act to either start, stop or change the amount that a particular gene is used, similar to how a green light, road block or stop sign direct traffic rules.

The process is critical for normal embryonic development and everyday cell processes.

If we can gain a deeper understanding of how species like the zebrafish are able to regenerate tissues when mammals cannot, despite having the same cell types, we may be able to start working to translate those mechanisms to mammals, she said. It is possible that certain regeneration pathways have been epigenetically silenced through evolution and we may be able to use modern advances in gene therapy techniques to unlock regenerative capacity in mammals.

Follow this link:
Anatomy of a grant: Ashley Kramer's yearlong journey to finding her doctoral thesis - The South End

The Challenge of Bioethics to Decision-Making in the UK – Westminster Abbey

Past Institute lectures

A lecture for the Von Hugel Institute series Ethics in Public Life, 5th February 2015, given by Claire Foster-Gilbert, Director, Westminster Abbey Institute.

The context of the series of lectures of which this is one is ethics in public life, and I would like to start by taking some time to describe the creation and operation of Westminster Abbey Institute, and use it as a prism for our consideration of bioethics and decision making in the UK. I want to say a little bit about the sacred-secular divide which I do not see. Then the two thorny examples I will use in bioethics, when I come to them, will be embryology and assisted dying.

Westminster Abbey Institute was launched in November 2013 to revitalize moral and spiritual values in public life, working with the public service institutions around Parliament Square, and drawing on its Benedictine resources of spirituality and scholarship.

Westminster Abbey sits on the south side of Parliament Square, with the Judiciary in the form of the Supreme Court on the west side, the Executive in the form of Whitehall on the north side, and the Legislature in the form of the Houses of Parliament on the east side. The Institute is the Abbeys answer to the question: what is it bringing to public service and how can it support those in public office?

We knew, when we started, what we were not: a think tank, part of the commentariat, a campaigning organisation, nor a fawning courtier. Nor were we apologists for religion in the public square. The Abbey is already more integrated than that. There is no sense of a sacred-secular divide, and as I go about my work as Director I feel none between my work and that of the public service institutions around the Square. The similarity is that we are identifying at the heart of the Parliament Square endeavour a sincere wish to support the good, to serve society, to make things better in the world. And in that sincere wish I see spirit moving, hearts opening, minds analysing, bodies acting, as a holistic, responsive flow to the call of public service.

I am not naive: the motivation to serve the public and the vocation to public service are not pure. In amongst the good wheat of service are the tares of motives such as selfish ambition, personal gain, fame, and the needy weakness of human nature to be recognised and rewarded. I see those other motives, but I know them for my own also, so am in no position the Abbey Institute is in no position, lets be clear to judge or condemn them. Like the parable, we leave that till the harvest. And meanwhile, by supporting the good, believing in the motives that are for service, recognising and applauding the rightness in the work around the Square, the murky tares, if I may torture the analogy beyond its capability, melt away. We hope.

I see a wholeness, then, responding to a call to serve. The deeper the response the more effective and lasting it will be and here is a place where our religion makes a specific contribution. The further back into God it reaches, the more effective and lasting and good the call to public service will be. I call it God. Spirit, depth, the swirling deep movement of creativity, the meditation of the soul, the rest before action. The further the archer draws back the bow, the further and truer the arrow will fly. It has been notable just how much of a longing for depth has shown itself in the people and institutions around the Square in the short time the Institute has been operating.

Our method is first to offer a Benedictine context. That is, we offer conversation that locates itself in stability, community and the conversion of manners. We will sit down with a group of, say, senior Civil Servants, or those tasked with offering professional development to MPs, or a group of Peers, and together we will devise a seminar for their department or group which will look at the good that the department or group is trying to do. What is significant and distinctive is that the psychological and philosophical location of the conversation is deep. That depth is also physically expressed by the Jerusalem Chamber where King Henry IV died and V became King, and the King James Version of the Bible was finalised, and so forth, where the seminars happen. Part of the Abbots and then the Deans lodging, a space where spiritual and worldly do not separate.

I was set a great example of how to do depth by Rowan Williams when he was the interlocutor for a series of four public conversations at St Pauls Cathedral, taking in turn global economy, ecology, governance and health, and asking the experts in those fields questions which immediately drew them into a consideration of the philosophical and even theological underlying currents of the subjects. The bishops did a similar thing with genetics experts when they spent a day learning about the subject. They were really good questions, and ones that practitioners, officials, public servants often dont have time to ask, but they are the most important questions because they lead us into our spiritual humanity.

A really lovely example emerged yesterday when we were sitting around the table in the Permanent Secretarys office of a Government Department, discussing a forthcoming seminar for the Department. One of the Civil Servants spoke about how too often officials in the Department will apply formulaic approaches, such as the benefit-cost ratio, in a way that masks or even undermines vital human qualities such as empathy and humility, and we will look at this in the seminar. Importantly, the words and the disposition came from the Civil Servant, not from the Abbey Institute. We are not functioning on the Square to tell others what the Good is. It emerges in the encounter.

So the conversation is located in a Benedictine place (in a way, for a short while, that Permanent Secretarys office became a Benedictine space). First, it is stable, it is safe here, and here is not going to go away, its an historical place where we can feel our own passing, gain a perspective on our place in history. Second, it is a place of community, which means that we are gathered in goodwill together, seeking the good together, united in our efforts and made companions in our purpose, not by any means agreeing with each other but feeling safe with each other. As a community of goodwill we feel it is safe to get things wrong, to take time to form conscience, to work things out. And of course we operate to the Chatham House rule. Third, we are about the conversion of manners. We expect transformation to take place though we dont necessarily know what it will be. Broadly, though, borrowing from Philip Shepherd, we will be looking for moves:

And I dont mind admitting that this transformation is probably only realised after the talking is over and everyone has gone to evensong and then wandered around the Abbey in the semidark and silence of the close of the day and had a glass of wine back in the Jerusalem Chamber!

In agreeing that we are a community of goodwill seeking to articulate the good I have offered an analogy from sailing that works well. A Government Department can be imagined as a sailing boat. At the helm stands the Permanent Secretary, who, like all good helmsmen, seeks never to steer the boat more than five degrees either side of the compass direction upon which the boat is set. Civil Servants in the Department form the crew, from the navigator who must know the course and ensure the helmsman anticipates obstacles, to the scrubber of decks who ensures no one slips up. All play their part in ensuring the boat remains shipshape and able to withstand the waves and the winds in travelling its appointed course.

The waves are the events of the nation and the world. They may be relatively calm or they may rise into steep and stormy mountains of water, threatening the stability of the boat.

The winds are public opinion, which can fill the sails of the boat and send it scudding on its chosen course. They can gust and buffet, interrupting the boats smooth journey. Or they can blow adversely, threatening to push the boat off course altogether.

Hence, the helmsman cannot simply hold the tiller fixedly. He or she must constantly respond and adjust to the wind and the waves, aiming to keep within five degrees either side of the compass direction or risk increasingly over-compensatory swings away from the course of travel.

The compass point towards which the boat is sailing is The Good. As such, it is not a destination; the journey is the thing, the direction of travel the concern, not the arrival.

By whom is The Good defined? It is true that the Government Minister is granted that responsibility and privilege by virtue of having been elected by universal franchise. But in defining The Good, Ministers have to have their Partys support. And of course the strength of the prevailing wind, public opinion, may be such as to determine a change of compass direction altogether. For the politician, public opinion will set parameters on what he or she can achieve. The great political leader will have a vision of the Good that transcends narrowminded concerns but retains Party support, and respects the parameters set by the prevailing wind of public opinion. The visionary and skilled politician will learn, quite possibly from his or her Civil Servants, about the art of tacking.

Because of course it is the helmsman and the crew who execute the tack, and any other sailing manoeuvres required. The Civil Service crew, having gathered the evidence sniffed the wind, watched the waves will need to be able to tell Ministers when their proposed direction of travel will not work: when, whatever the Ministers might want to think, their proposed direction is possibly not towards The Good. Thus the Good is sought by all.

And in passing, if one imagines Whitehall as a fleet of boats, those, too, will need to be taken into account by the helmsman. But and it is a wonderful sight sailing boats, journeying as a fleet in the same direction across the waves, subject to the same wind, stay uniform distances apart.

Having established a common concern with identifying the Good, seated in our Benedictine space, we then spend time as moral philosophers, looking at the specifics of the policy drivers for a given Government Department. Our analysis is rigorous, using the method I developed in the Centre of Medical Law and Ethics at Kings College, London, under Ian Kennedy, in the 1990s.

We use the three broad approaches that moral philosophers have taken over the centuries as they have sought to determine what is good. These we have called goal-based, duty-based and right-based, following Dworkinii, Botrosiii and Fosteriv. Very briefly and broadly, a goal-based thinker will see the good of an action in its consequences rather than in the content of the action itself; a duty-based thinker will look at the action and judge it according to preexisting moral rules; and a right-based thinker will judge the action according to the views of those most affected by it. The goal-based approach is valid insofar as it is the case that we rarely act without some end in view and it is right to consider whether that end is a good one. The goal-based approach is limited in that even very desirable goals should not justify actions which in themselves are intrinsically nasty. The ends are important moral considerations but they dont justify the means. Morality is not a mathematical exercise. The duty-based approach is valid in that it makes us think hard about what we are doing rather than merely why we are doing it, recalibrating the needle of our moral compass, making us morally sensitive rather than mathematically certain. The duty-based approach is limited because it can blind us to important consequences (Kant would have us truthfully respond to a murderer seeking her prey); and it is limited because it can make us arrogant: concerned only with our own place in heaven earned by doing the right thing, regardless of its effect or the views of others (the poor soul who will be murdered because Kant refused to tell a lie, or the patient who wants his life support switched off and we refuse to take a life). The right-based approach is valid because it requires us to listen to others, it makes us community-minded instead of purist. It is limited because on its own it would make someones request, for example, to take their life, right with no other consideration except that it is their wish.

All three approaches are needed. They conflict, they make us think, they require sensitive responses, honest appraisal, self-awareness because we will temperamentally favour one approach over the others, but taken together they form a three-legged stool that stands firm, if the legs are all of the same length, even on rocky ground.

And then comes the real challenge of bioethics. The Department of Health wants us all to live better for longer. But when does life begin and when does it end? I want in this third and final part of my lecture to explore the contemporary challenge of these questions by looking at two issues embryology and assisted dying that have been working their way around Parliament Square, with cases in the Supreme Court, policy development in Whitehall, and legislation or attempts at legislation in the Houses of Parliament.

Human fertilisation and embryology are scientifically complex and they are also, at every stage, morally sensitive. The challenge to Government and Parliament has been whether and how to draw these extraordinary scientific developments within a regulatory framework in a way that respects the science and does not ride roughshod over the sensitive moral questions, or ban the research and practice altogether. Having chosen the former course of action, what principles needed to underlie the regulatory framework?

Let us take a step back in time and thought. Let us bring the issue into our safe Benedictine space. Here we are allowed to think out aloud. We do not have to have a pre-determined position, but if we do, we wont be shouted down or assumed to be on the side of the devil.None need feel defensive. In this Benedictine space we are seeking the Good, aware that many have tried before us and God willing there will be many afterwards, all calibrating their moral compass and seeking to steer the boat no more than five degrees either side of the compass point, but having to allow, because of the wind of public opinion and the waves of ever changing events, that much leeway either side. We know we will not find perfect answers.

And now for the three-legged framework. From a goal-based perspective, we ask what embryology is for, and why it matters. Embryology is important as a cure for infertility, as a therapeutic response to currently incurable diseases using cell transplantation and, very recently proposed, eliminating mitochondrial disease altogether. Its goals, then, are for life: new life, and curing diseased life. No one, really, could argue with the goals of embryology. We would want the research and practice to be done excellently, so as to ensure these good goals were reached, but from a goal-based perspective, taken on its own, there can be no quarrel with it.

From a duty-based perspective, what does embryology involve? Here the moral questions start to bite. The first question must be about the status of the embryo itself. Because if the embryo has the same status as a human life, no matter how wonderful the goals are, no one would countenance destroying a human life to reach them, and embryology (which always involves destroying embryos) would fall at this moral fence.

The reasons you might regard the embryo as a human life are as follows: the embryo is formed from the fertilisation of an egg by a sperm forming a unique genome no one (if it is a person) was ever like it before, and no one will be ever again. We, each of us diverse people, were all embryos once. If we are to choose a point when life begins, the formation of the fertilised egg is certainly a definite stage one could choose.

The reasons you might not regard the embryo as human life are: the place of fertilisation is not the womb or the field in which the embryo is implanted, but at the base of the fallopian tubes. The embryo still has a journey to make to reach the womb and implant. (Some Shia teaching on this argues that life cannot be said to have begun until the seed, egg and field are all in place, ie at implantation.) During that journey, in the normal course of events, 70% of embryos do not reach the womb. It is during that journey that the all-important stem cells start to proliferate, hence the interest in the early, pre-implanted embryo, not the fetus in the womb. During that journey, the embryo may divide and become more than one fetus, hence genetically identical twins. These reasons may persuade you that it would be acceptable to see the early embryo not as human life but as potential life, and that its use therapeutically is acceptable. You may feel the goal-based tug: the status of the early embryo is in question, and the use of them therapeutically is so full of promise Should the duty-based consideration, that the embryo has independent moral status like that of a human being, give way?

What is important to recognise is that we do not say that the embryo has no status. The legislation has recognised its moral importance by regulating its use. But the law has accepted that the embryo is not the same as a human life.

From a right-based perspective, you cannot really make a judgement. The embryo cannot speak for itself. Is it fanciful to conduct a thought-and-feeling experiment predicated on the fact that we were all embryos once. Would we be happy to have been destroyed even before reaching the womb, to save another life or lives, or to create a new life? ??

The other right-based question relates to those who might benefit from stem cell or mitochondrial therapy: if they think of the embryo as having human status they may not want to benefit from such treatment. Healthcare practitioners may seek to be conscientious objectors.

The challenge to UK decision-making of embryology has been profound and I think, myself, that we have not done badly at it. Prior to this last development on mitochondrial DNA, the debates have been long and thoughtful, no speedy legislation was drawn up (except to prevent cloning), and the regulation is careful. In the UK, embryo research can take place but it is all regulated. (In the US, embryo research may not take place if it is federally funded; if you can pay for it yourself, you can do what you like!)

However, courts continue to be referred to as no legislation could possibly anticipate the science. It has turned out that the most fruitful source of embryonic stem cells has not come from embryos but from de-differentiated adult cells. Since however these de-differentiated cells, if placed in a womb, could theoretically grow into a clone of the person whose cell it was, this has had to be specifically outlawed and, much more recently, and potentially worryingly, a court has ruled that: The mere fact that a parthenogenetically activated human ovum commences a process of development is not sufficient for it to be regarded as a human embryo. This judgement opens the way to patenting the process of creating stem cells. It is potentially worrying since it arguably robs the embryo of its moral status. However, what is the status of a de-differentiated cell, which could originate from any one of the bodies in this room just by scraping our skin?

Is the very recent decision of the Commons to allow the process that removes diseased mitochondrial DNA from the offspring of mothers with the disease a case of slipping down a slippery slope into unethical waters? Is it the first step towards eugenics, since it eliminates the disease from the germ line permanently? Or is it an intelligent use of skills and techniques we have developed through carefully regulated embryo research, that will allow the cure of a vile disease?

Assisted dying, unlike embryo research, has not been made legal and given a set of regulations by which to abide. Despite its repeated return to Parliament and the apparent public support for a change in the law, none has happened, as yet. In practice, cases have been decided by the Courts and the number of cases coming to the Courts is only increasing. It is something of a sore point for the judges: they cannot turn cases away. All the time, as they see it, Parliament refuses to take the bull by the horn and create legislation, they are obliged to give judgements on a case by case basis that creepingly changes the law, and it is changed by lawyers not by democratically elected representatives of the public debating in public.

Before reflecting on the challenge to law and policy-makers that assisted dying has posed, let us once again step back into our Benedictine space, and we should pause here for a moment and recollect that the primary quality of that space is listening

And now conduct our analysis. Assisted dying is the act of making available to a person, who has expressly and competently asked for it, the means to take his or her life by their own hand.

From a goal-based perspective, one goal of assisted dying is to alleviate suffering. Another is torespect the autonomy of individuals. Another may be put more boldly: to end life deliberately.

From a duty-based perspective, principles of the sanctity of life and of respecting autonomy both raise their concerns, and conflict. How are they resolved?

From a right-based perspective, the principle of respect for autonomy trumps any duty of other individuals to save, sustain or end life. It is, simply, up to the individual. When polls are taken on the subject of assisted dying and euthanasia the vast majority of responses are in favour of it, on the grounds, though, that it is my life to do with as I please and who is any doctor to prevent me. But a law that permitted a solely right-based approach that the request should be granted simply because it had been made would be impossible to apply. It would be impossible to know if the person had actually asked for death, because they would be dead. Additional safeguards have to be included in any legislation, and these require that certain relevant professionals are satisfied that the conditions allowing assisted dying are met. This is not, then, a purely rights-based activity any more. Similar difficulties arise in seeking abortion - it is not, in the legislations, simply up to the mother whether or not the abortion takes place. She has to satisfy two doctors that she fulfils the criteria set by the law. The fact that doctors will very often sign the forms without questioning the mother, because they take a right-based approach in profoundly believing in her right to choose, is symptomatic of the challenge of lawmaking in areas of bioethics.

If the dying in question is assisted only, ie the person has to take the lethal substance themselves, this right-based problem is allayed. That is to say, we may be fairly sure that if the pink drink given by organisations such as Dignitas is drunk without assistance once it is put in the hands of the one seeking assisted dying, then he or she most definitely did want to die.

We cannot know what passes in their hearts however, and Mary Warnock has been worryingly at ease with the idea that it would be perfectly all right to seek euthanasia on the grounds that one felt a burden to ones family and friends. The wishes and needs of the community of that individual: family, loved ones, society are all included in the right-based approach, and what of these? Chaplains ministering to those receiving euthanasia in Holland speak of the devastation of families, resonant of the desolation of the families of suicides.

The most recent case that came to the Supreme Court was that of Nicklinson, Lamb and the Director of Public Prosecutionv. Nicklinson and Lamb were both almost entirely paralysed; Nicklinson from a stroke which left him able to blink only and Lamb from an accident that meant he could only move his right hand. Hence neither would be able to take the pink drink unaided, so both wished to be assisted to die without fear of prosecution of those who helped. The Director of Public Prosecution sought the freedom to decide on the matter of assisting suicide on a case by case basis.

In the Supreme Court, all the Law Lords agreed that Article 8 of the Human Rights Act (which is the right to a private life, to be overridden only in the case of threats to public safety or criminal acts) is relevant to the issue of assisting someone to die if it is their express wish. That is to say, domestic rulings can be made by way of interpretation of the Article in relation to assisted suicide. But while some Law Lords believed that it was a right for a person to be assisted to die if it was their express wish, according to Article 8, others did not. It was recognised that there was a fundamental incompatibility between the sanctity of life and autonomy. Several Law Lords argued strongly that the debate should be held in Parliament as the representative body of society, not judged upon by appointed Justices. And indeed there is yet another bill to allow assisted dying making its way through the House of Lords now. It has reached the stage where the Lords are working through more than 100 amendments, some of which are clearly intended to wreck the bill, whilst others provide clarification and strengthening of safeguards. And arguably the intellectual purity of the moral reasoning of the judges is a better place to turn to than the mess of Parliamentary debate. What a strange way for law on such a sensitive and controversial issue as the management of the dying process to be written: by the tug of war of differing factions and the compromise that will inevitably be reached if the bill is to succeed.

And yet, how are we to decide these matters that affect us all? I should like to finish, provocatively, with a lengthy quotation from a recent lecture delivered by one of the Justices of the Supreme Court, Lord Sumption.

To sum up, then. We have considered challenging and complex bioethical issues using the Westminster Abbey Institute approach of first, creating a Benedictine space of safety and stability, second, subjecting the matter to rigorous moral analysis and third, coming to a decision, which decisionmaking is the responsibility of the lawmakers and the policymakers. What I have not done is to offer absolute rules or principles which trump every other consideration. It is far better to be morally sensitive than to be morally certain. And so I am agreeing with Lord Sumption that, however fallible it may be, Parliament is the place to fashion legislation on these matters. We do well to attend to whom we put there.

(i) Philip Shepherd, New Self, New World: recovering our senses in the twenty-first century, (Berkeley: North Atlantic Books), 2010 (p 282)(ii) Ronald Dworkin, Taking Rights Seriously, 1977 (Harvard: Harvard University Press)(iii) Sophie Botros and Claire Foster, The moral responsibilities of research ethics committees, in Dispatches, 3:3, Summer 1993(iv) Claire Foster, The Ethics of Medical Research on Humans, (Cambridge: Cambridge University Press) 2001(v)R (on the application of Nicklinson and another) (Appellants) v Ministry of Justice (Respondent); R (on the application of AM) (AP) (Respondent) v The Director of Public Prosecutions (Appellant); R (on the application of AM) (AP) (Respondent) v The Director of Public Prosecutions (Appellant) 25 June 2014(vi) Lord Sumption, The Limits of Law, 27th Sultan Azlan Shah Lecture, Kuala Lumpur, 20 November 2013

Download a transcript of this lecture (PDF, 238KB)

Continue reading here:
The Challenge of Bioethics to Decision-Making in the UK - Westminster Abbey

Platelet-rich plasma therapy (PRP): Costs, side effects …

Platelet-rich plasma therapy has made headlines, often because it is favored by elite athletes to help them recover from injury.

Some doctors are now using platelet-rich plasma therapy or PRP injections for several reasons, from encouraging hair growth to promoting soft tissue-healing.

However, research studies have not definitively proved that PRP works for the conditions it is reported to benefit. In this article, we have a look at the case for PRP, and the costs involved.

Platelets are blood cells with several roles to play in the body.

One is to promote blood clotting so that a person does not excessively bleed when they are cut.

Another is to contain proteins in the blood that help wounds to heal.

Researchers theorize that by injecting areas of inflammation or tissue damage with high concentrations of platelets, it can encourage wounds to heal.

A small blood sample is taken from the person being treated and put into a centrifuge or other specialized device that spins at high speed. This process separates platelets from other blood components. The concentration of platelets is then injected into the area of the persons body that needs to be treated.

Because the injection contains a high concentration of platelets, which can be from 5 to 10 times more than the untreated blood, doctors theorize that the platelets will speed up healing.

Some examples of treatment areas where PRP has been used include:

Doctors have injected PRP into the scalp, as a way of reducing the inflammation that can lead to hair loss.

Doctors first used PRP to help people heal after jaw and plastic surgeries. Examples of tissues that PRP has been used on include:

Ligaments can take time and be difficult to heal, which can make PRP an attractive option for some of those who have experienced injuries to this tissue group.

Doctors have used PRP to reduce inflammation caused by osteoarthritis. This inflammation can lead to joints becoming painful and stiff.

Research studies about PRP include:

Doctors are also trying to use PRP to heal broken bones, but no research has yet proven its effectiveness in this area.

Costs for PRP treatment are reported to be between $500 and $2,000.

It is not typically covered by insurance because of the lack of evidence, so far, to conclusively prove that it works.

Also, costs can vary depending on location, facilities, and the expertise of the doctor performing the treatment. Often, a person will have multiple injections given 2 to 3 months apart.

Some of the worlds most elite athletes have used PRP for wound healing. They include golfs Tiger Woods, baseballs Takashi Saito, and footballs Hines Ward and Troy Polamalu.

As injecting PRP involves using a persons own platelets, they do not usually experience any adverse reactions to the injections. However, it is possible that a person may have irritation, pain, or bleeding related to the injection site.

Most people can resume their normal activities almost immediately after having a PRP injection. The average time from blood-drawing to the injection itself is about half-an-hour.

While PRP is a promising therapy for those who experience tissue damage or hair loss, large-scale research studies are needed to establish the effectiveness of treatments.

With larger studies than those to date, doctors could identify a dose or injection routine that works best for treating injuries or other conditions. Also, further studies could help doctors determine what symptoms to exclude from PRP injections.

Until that time, PRP injections are likely to remain a controversial therapy not covered by medical insurance, the costs of which, people are required to pay for themselves.

The rest is here:
Platelet-rich plasma therapy (PRP): Costs, side effects ...

New informative research on Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market 2020 | Major Players: Orange County Hair Restoration…

This industry research presents the Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market size, historical breakdown data (2014 2019) and forecast (2020 2025). This report provides the estimation of market size and volume. Both top-down and bottom-up approaches have been used to estimate and validate the market size of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market. For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

The Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Market study on the global market will encompass the entire ecosystem of the industry, covering five major regionsand the major countries falling under those regions.

Download Exclusive Free Sample PDF Report at https://inforgrowth.com/sample-request/5930924/stem-cell-and-platelet-rich-plasma-prp-alopecia-th

Following Top Key players are profiled in the report:Orange County Hair Restoration Center, Hair Sciences Center of Colorado, Anderson Center for Hair, Evolution Hair Loss Institute, Savola Aesthetic Dermatology Center, Virginia Surgical Center, Hair Transplant Institute of Miami, Colorado Surgical Center & Hair Institute.

The Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market report analyzes and researches the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies development status and forecast in United States, EU, Japan, China, India and Southeast Asia.

Market Segmentation:

The Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market report focuses on global major leading industry players providing information such as company profiles, product picture, and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis are also carried out.

On the basis of products, the report split into: Platelet Rich Plasma Injections, Stem Cell Therapy

On the basis of the end users/applications:Dermatology Clinics, Hospitals

Get Special Discount Up To 50%,https://inforgrowth.com/discount/5930924/stem-cell-and-platelet-rich-plasma-prp-alopecia-th

Key Stakeholders as per this report are Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Manufacturers, Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Distributors/Traders/Wholesalers, Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Subcomponent Manufacturers, Industry Association, Downstream Vendors.

The Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies industry development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects are assessed and overall research conclusions offered.

With the tables and figures, theStem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Furthermore, this Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market study will help our clients solve the following issues:

This study will address some of the most critical questions which are listed below:

Get Complete TOC: https://inforgrowth.com/enquiry/5930924/stem-cell-and-platelet-rich-plasma-prp-alopecia-th

Contact Us: Contact Person: Rohan S. Email:[emailprotected] Call: US: +1-909-329-2808 UK: +44-203-743-1890

Go here to see the original:
New informative research on Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market 2020 | Major Players: Orange County Hair Restoration...